FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210343726> ?p ?o ?g. }

• W3210343726 endingPage "e57" @default.
• W3210343726 startingPage "e57" @default.
• W3210343726 abstract "<h3>Purpose/Objective(s)</h3> Radiation therapy (RT) remains a critical treatment modality for unresectable hepatocellular carcinoma (HCC), with proton beam therapy (PBT) being widely utilized due to its decreased exit dose compared to photon-based RT. We hypothesize that patients with HCC receiving definitive PBT would experience decreased acute toxicity when compared to those receiving photon-based RT. <h3>Materials/Methods</h3> Electronic medical records were retrospectively reviewed at a single institution for patients diagnosed with unresectable HCC and treated with definitive RT between 1/2011 and 12/2020. Patients treated with prior surgery or radiofrequency ablation were excluded. Progress notes and treatment summaries were reviewed to determine baseline characteristics including age at diagnosis, Child-Pugh classification (CPC), AJCC 8^th edition T stage, performance status, and RT dose. Acute treatment toxicities were evaluated using Common Terminology Criteria for Adverse Events v5.0. Descriptive statistics were quantified for baseline characteristics. Odds ratios (OR) with 95% confidence intervals (CI) were generated to determine the association between PBT vs. photon therapy and acute radiation toxicities in bivariate and multivariate logistic regression models. <h3>Results</h3> Forty-six patients were included in the analysis. 24 (52%) patients received PBT while 22 (48%) received photon-based RT. Median age for the PBT and photon-based RT groups were 67 (interquartile range (IQR): 58.6 to 72.5) and 65.5 years (IQR: 61.0 to 73.0), respectively (<i>P</i> = 0.991). 50% of patients who received PBT had a T stage greater than T2, compared to 71% of patient in the photon group (<i>P</i> = 0.148). 42% of the PBT group had CPC B or worse, compared to 38% in the photon group (<i>P</i> = 0.813). Performance status and total dose did not significantly differ between groups (<i>P</i> = 0.351 and <i>P</i> = 0.773, respectively). PBT was associated with higher odds of any grade radiation dermatitis (RD) (OR = 6.00, 95% CI: 1.13 to 31.9) and lower odds of any grade anorexia (OR = 0.21, 95% CI 0.05 to 0.91). Odds of any grade diarrhea and fatigue, did not significantly differ between groups (<i>P</i> = 0.086 and <i>P</i> = 0.958, respectively). After controlling for performance status, total dose, T stage, CPC, and age at diagnosis, PBT was still associated with higher odds of RD (OR = 11.07, 95% CI: 1.14 to 107.71) and lower odds of anorexia (OR = 0.14, 95% CI: 0.02 to 0.93). <h3>Conclusion</h3> This study provides evidence that although PBT appears to have a superior safety profile in regard to acute anorexia, patients treated with PBT have higher odds of acute RD; these effects persist even after controlling for relevant confounding factors. PBT may result in fewer GI toxicities at the cost of greater skin toxicity." @default.
• W3210343726 created "2021-11-08" @default.
• W3210343726 creator A5002512959 @default.
• W3210343726 creator A5010131203 @default.
• W3210343726 creator A5012650103 @default.
• W3210343726 creator A5015750678 @default.
• W3210343726 creator A5027420024 @default.
• W3210343726 creator A5033421466 @default.
• W3210343726 creator A5039831151 @default.
• W3210343726 creator A5047523417 @default.
• W3210343726 creator A5049531670 @default.
• W3210343726 creator A5052836295 @default.
• W3210343726 creator A5056241109 @default.
• W3210343726 creator A5061968093 @default.
• W3210343726 creator A5069565044 @default.
• W3210343726 creator A5069585958 @default.
• W3210343726 creator A5072132607 @default.
• W3210343726 creator A5081233015 @default.
• W3210343726 creator A5086998930 @default.
• W3210343726 creator A5090718807 @default.
• W3210343726 date "2021-11-01" @default.
• W3210343726 modified "2023-10-16" @default.
• W3210343726 title "Comparing Acute Toxicities of Patients With Unresectable Hepatocellular Carcinoma Treated With Definitive Proton vs. Photon-Based Radiotherapy" @default.
• W3210343726 doi "https://doi.org/10.1016/j.ijrobp.2021.07.399" @default.
• W3210343726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701773" @default.
• W3210343726 hasPublicationYear "2021" @default.
• W3210343726 type Work @default.
• W3210343726 sameAs 3210343726 @default.
• W3210343726 citedByCount "0" @default.
• W3210343726 crossrefType "journal-article" @default.
• W3210343726 hasAuthorship W3210343726A5002512959 @default.
• W3210343726 hasAuthorship W3210343726A5010131203 @default.
• W3210343726 hasAuthorship W3210343726A5012650103 @default.
• W3210343726 hasAuthorship W3210343726A5015750678 @default.
• W3210343726 hasAuthorship W3210343726A5027420024 @default.
• W3210343726 hasAuthorship W3210343726A5033421466 @default.
• W3210343726 hasAuthorship W3210343726A5039831151 @default.
• W3210343726 hasAuthorship W3210343726A5047523417 @default.
• W3210343726 hasAuthorship W3210343726A5049531670 @default.
• W3210343726 hasAuthorship W3210343726A5052836295 @default.
• W3210343726 hasAuthorship W3210343726A5056241109 @default.
• W3210343726 hasAuthorship W3210343726A5061968093 @default.
• W3210343726 hasAuthorship W3210343726A5069565044 @default.
• W3210343726 hasAuthorship W3210343726A5069585958 @default.
• W3210343726 hasAuthorship W3210343726A5072132607 @default.
• W3210343726 hasAuthorship W3210343726A5081233015 @default.
• W3210343726 hasAuthorship W3210343726A5086998930 @default.
• W3210343726 hasAuthorship W3210343726A5090718807 @default.
• W3210343726 hasBestOaLocation W32103437261 @default.
• W3210343726 hasConcept C119060515 @default.
• W3210343726 hasConcept C126322002 @default.
• W3210343726 hasConcept C156957248 @default.
• W3210343726 hasConcept C197934379 @default.
• W3210343726 hasConcept C2777793932 @default.
• W3210343726 hasConcept C2778019345 @default.
• W3210343726 hasConcept C2989005 @default.
• W3210343726 hasConcept C509974204 @default.
• W3210343726 hasConcept C71924100 @default.
• W3210343726 hasConceptScore W3210343726C119060515 @default.
• W3210343726 hasConceptScore W3210343726C126322002 @default.
• W3210343726 hasConceptScore W3210343726C156957248 @default.
• W3210343726 hasConceptScore W3210343726C197934379 @default.
• W3210343726 hasConceptScore W3210343726C2777793932 @default.
• W3210343726 hasConceptScore W3210343726C2778019345 @default.
• W3210343726 hasConceptScore W3210343726C2989005 @default.
• W3210343726 hasConceptScore W3210343726C509974204 @default.
• W3210343726 hasConceptScore W3210343726C71924100 @default.
• W3210343726 hasIssue "3" @default.
• W3210343726 hasLocation W32103437261 @default.
• W3210343726 hasLocation W32103437262 @default.
• W3210343726 hasOpenAccess W3210343726 @default.
• W3210343726 hasPrimaryLocation W32103437261 @default.
• W3210343726 hasRelatedWork W2059674080 @default.
• W3210343726 hasRelatedWork W2061253854 @default.
• W3210343726 hasRelatedWork W2233648844 @default.
• W3210343726 hasRelatedWork W2520565670 @default.
• W3210343726 hasRelatedWork W2752827782 @default.
• W3210343726 hasRelatedWork W3031152052 @default.
• W3210343726 hasRelatedWork W3091031604 @default.
• W3210343726 hasRelatedWork W3091367366 @default.
• W3210343726 hasRelatedWork W3192669160 @default.
• W3210343726 hasRelatedWork W4307349053 @default.
• W3210343726 hasVolume "111" @default.
• W3210343726 isParatext "false" @default.
• W3210343726 isRetracted "false" @default.
• W3210343726 magId "3210343726" @default.
• W3210343726 workType "article" @default.